Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E.
Other stock markets
 03:05:13 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.65 CAD -1.69% Intraday chart for HLS Therapeutics Inc. -6.06% +17.72%
Apr. 08 HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA CI
Mar. 14 Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024

Evolution of the average Target Price on HLS Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

d2cfaf38d1ba5615dd70e65c9.GHW0JU_yfYvQVDm5zjUykhZqiT4DAIlRRbNCSJ-5CPo.XkGBVz6aONuebHPpu3QEx2cb4nBXM8UGKtRvAO6KQJxLJudNDccO7rQVSg~b537566044503f70c33a03d4c0698ba9

Analyst Recommendations on HLS Therapeutics Inc.

HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00 MT
HLS Therapeutics Buy Rating Maintained at Stifel GMP as Growth Expectations Eased; Price Target Cut to C$12.25 MT
HLS Therapeutics Brief: Announcing Updates to its Credit Agreement; Term Extended, Borrowing capacity increases, Financial flexibility improves, and Interest rates remain relatively unchanged MT
HLS Therapeutics Buy Rating Reiterated at Stifel GMP as Vascepa Prescriptions Rise; Price Target Kept at C$26.00 MT
HLS Therapeutics Reiterated at Buy at Stifel GMP on Rising Sales; Price Target Kept at C$32.00 MT
HLS Therapeutics Keeps Buy Rating at Stifel GMP Following Q2 Results; Price Target Cut to C$32.00 MT
HLS Therapeutics Buy Rating Maintained by Stifel GMP as Vascepa Sales Expand MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.397 USD
Average target price
4.5 USD
Spread / Average Target
+32.48%
High Price Target
7.768 USD
Spread / Highest target
+128.68%
Low Price Target
3.081 USD
Spread / Lowest Target
-9.30%

Consensus detail

Consensus revision (last 18 months)

Analysts covering HLS Therapeutics Inc.

Stifel GMP

Ratings for HLS Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. HLS Stock
  4. Consensus HLS Therapeutics Inc.